Company Description
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.
The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington’s disease.
It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 28, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | William Chou |
Contact Details
Address: One Commerce Square, 2005 Market Street Philadelphia, Pennsylvania 19103 United States | |
| Phone | (267) 866-0311 |
| Website | passagebio.com |
Stock Details
| Ticker Symbol | PASG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001787297 |
| CUSIP Number | 702712100 |
| ISIN Number | US7027121000 |
| Employer ID | 82-2729751 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. William Chou M.D. | President, Chief Executive Officer and Director |
| Dr. Karl Whitney Ph.D. | Senior Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | ARS | Filing |
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | 144 | Filing |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 5, 2025 | 424B5 | Filing |
| Mar 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |